Compare Stocks: GPCR, ELAN, CORT, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.81B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.67B	0.45	1.40 million shs	769,035 shs
ELAN Elanco Animal Health	$22.06 -8.9%	$24.70	$16.15 ▼ $27.98	$12.09B	1.67	6.02 million shs	22.07 million shs
GPCR Structure Therapeutics	$53.14 +1.0%	$47.63	$15.86 ▼ $94.90	$3.74B	-1.43	558,888 shs	329,459 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.24%	-2.41%	-13.37%	-2.13%	+106.02%
CORT Corcept Therapeutics	+2.61%	-3.25%	+19.18%	+111.88%	+57.08%
ELAN Elanco Animal Health	-8.96%	-16.52%	-10.69%	-6.28%	+57.19%
GPCR Structure Therapeutics	+0.99%	+10.62%	-3.19%	+35.91%	+225.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.81B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.67B	0.45	1.40 million shs	769,035 shs
ELAN Elanco Animal Health	$22.06 -8.9%	$24.70	$16.15 ▼ $27.98	$12.09B	1.67	6.02 million shs	22.07 million shs
GPCR Structure Therapeutics	$53.14 +1.0%	$47.63	$15.86 ▼ $94.90	$3.74B	-1.43	558,888 shs	329,459 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.24%	-2.41%	-13.37%	-2.13%	+106.02%
CORT Corcept Therapeutics	+2.61%	-3.25%	+19.18%	+111.88%	+57.08%
ELAN Elanco Animal Health	-8.96%	-16.52%	-10.69%	-6.28%	+57.19%
GPCR Structure Therapeutics	+0.99%	+10.62%	-3.19%	+35.91%	+225.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$265.55	24.82% Upside
CORT Corcept Therapeutics	2.63	Moderate Buy	$119.17	7.58% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$29.09	31.88% Upside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	108.71% Upside

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, CORT, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00
8/6/2026	ELAN Elanco Animal Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $33.00
8/6/2026	ELAN Elanco Animal Health	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$29.00 ➝ $30.00
7/31/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$310.00 ➝ $306.00
7/30/2026	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $165.00
7/30/2026	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $165.00
7/29/2026	CORT Corcept Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $150.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	17.15	N/A	N/A	$1.75 per share	121.57
CORT Corcept Therapeutics	$830.81M	14.41	$0.93 per share	119.58	$6.53 per share	16.96
ELAN Elanco Animal Health	$4.72B	2.34	$2.11 per share	10.43	$13.19 per share	1.67
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$24.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	52.40	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	263.74	47.14	N/A	6.52%	8.26%	6.45%	N/A
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	17.37	1.45	-3.96%	8.13%	3.99%	N/A
GPCR Structure Therapeutics	-$141.20M	-$0.87	N/A	N/A	N/A	N/A	-26.12%	-24.85%	N/A

Latest GPCR, ELAN, CORT, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	N/A	N/A	N/A	$221.11 million	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	2.27	1.39	1.32
CORT Corcept Therapeutics	N/A	2.86	2.77
ELAN Elanco Animal Health	0.58	2.05	1.12
GPCR Structure Therapeutics	N/A	26.16	26.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
ELAN Elanco Animal Health	97.48%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
ELAN Elanco Animal Health	1.14%
GPCR Structure Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.76 million	Optionable
GPCR Structure Therapeutics	136	71.07 million	67.17 million	Optionable

GPCR, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00

August 7 at 4:29 PM | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Given New $110.00 Price Target at Citizens Jmp

August 7 at 10:59 AM | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages

August 7 at 4:13 AM | marketbeat.com

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 7 at 1:28 AM | finance.yahoo.com

Avidity Partners Management LP Buys Shares of 30,000 Structure Therapeutics Inc. Sponsored ADR $GPCR

August 1, 2026 | marketbeat.com

Wall Street Zen Upgrades Structure Therapeutics (NASDAQ:GPCR) to "Sell"

August 1, 2026 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen

August 1, 2026 | marketbeat.com

Janus Henderson Group PLC Purchases 264,833 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 31, 2026 | marketbeat.com

Structure Therapeutics (GPCR) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Stempoint Capital LP Cuts Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 30, 2026 | marketbeat.com

Rock Springs Capital Management LP Sells 108,019 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 28, 2026 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

A small-cap contender looking to challenge the weight-loss drug giants

July 24, 2026 | msn.com

PSquared Asset Management AG Buys Shares of 35,000 Structure Therapeutics Inc. Sponsored ADR $GPCR

July 24, 2026 | marketbeat.com

Siren L.L.C. Acquires 250,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

July 24, 2026 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Monashee Investment Management LLC

July 23, 2026 | marketbeat.com

SEB Asset Management AB Purchases New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 21, 2026 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading 4.8% Higher - Here's Why

July 17, 2026 | marketbeat.com

Principal Financial Group Inc. Grows Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

July 17, 2026 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 13, 2026 | marketbeat.com

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

July 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, ELAN, CORT, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$212.74 +2.61 (+1.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$211.84 -0.90 (-0.42%)

As of 08/7/2026 07:59 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$110.77 +2.82 (+2.61%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$111.03 +0.26 (+0.23%)

As of 08/7/2026 07:45 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health NYSE:ELAN

$22.06 -2.14 (-8.85%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$22.33 +0.27 (+1.23%)

As of 08/7/2026 07:54 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Structure Therapeutics NASDAQ:GPCR

$53.14 +0.52 (+0.99%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$55.42 +2.28 (+4.30%)

As of 08/7/2026 07:40 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, CORT, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPCR, ELAN, CORT, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPCR, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, ELAN, CORT, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Structure Therapeutics NASDAQ:GPCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GPCR, ELAN, CORT, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GPCR, ELAN, CORT, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GPCR, ELAN, CORT, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, ELAN, CORT, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Structure Therapeutics NASDAQ:GPCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools